Venrock Healthcare Capital Partners

Venrock Healthcare Capital Partners invests across both private and public healthcare companies. The firm participates in private financing rounds from Seed through late-stage Growth and also takes positions in publicly traded biotech, diagnostics, and digital health companies, often via crossover rounds or open-market purchases when scientific or regulatory catalysts align with the partnership’s domain expertise.

The firm focuses on therapeutics—including genetic medicines, oncology, and radiopharmaceuticals—along with medical devices, diagnostics, and digital health. It has publicly discussed conviction in AI-enabled drug discovery, translational biology platforms, and care-delivery models that reduce clinical friction. Historically, it has avoided pure health-insurance or hospital-operating company investments in favor of innovation-driven asset classes.

Venrock Healthcare Capital Partners operates within Venrock’s overall fund structure rather than as a separately branded fund management company. The healthcare strategy receives discrete partnership-level leadership and investment committee authority. The firm has not disclosed a standalone healthcare-only fund close, but Shah and Koh’s team drives the sector allocation from within the broader Venrock partnership.

Venrock Healthcare Capital Partners regularly syndicates with top-tier crossover and life-science specialists, including blue-chip biotechnology funds and public-market healthcare investors. The partnership values collaborative financing rounds that aggregate domain-specific due diligence, and Venrock’s technology-side partners occasionally join syndicates when a portfolio company sits at the intersection of biology and software.